Subscribe today to receive notice of our latest thought leadership, articles, blogs and updates.
Insights
Blogs
Sharing perspectives leads to greater understanding and fuels innovation
Check out our latest blog posts:
|
May 18, 2023 · Medicare Insights Team
On April 27, 2023, CMS released the NGHP Applicable Plan Appeals Reference Guide as a way to streamline the appeal process, which includes types of appeals and documentation needed to support appeals. Read more... |
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
|
May 04, 2023 · Public Policy & Regulatory Affairs Team
Brief updates include Michigan auto fee schedule CPI adjustment and Montana proposed updates to work comp treatment guidelines and formulary. Read more... |
|
|
May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more... |
|
|
May 01, 2023 · Clinical Team
Akorn Operating Company LLC filed Chapter 7 bankruptcy and the company has ceased all operations, including the discontinuation of the quality activities of these marketed drug products. Read more... |
|
|
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more... |
|
|
April 14, 2023 · Public Policy & Regulatory Affairs Team
Brief updates on policy developments across the country, including Oregon workers’ comp updated rules, and Virginia workers’ comp cancer presumption and anxiety disorder bills. Read more... |
|
|
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more... |
Page 6 of 19
